Evogene Ltd. reports developments as a computational chemistry company focused on generative design of small molecules for pharmaceutical and agricultural applications. Its recurring updates center on ChemPass AI™, a proprietary generative AI platform used to explore chemical space and optimize small-molecule candidates across multiple parameters.
Company news also covers financial results, strategic refocusing around ChemPass AI™, collaborations in drug discovery and ag-chemical development, and subsidiary activity. Reported subsidiary themes include Casterra's castor seed varieties and castor farming systems for bio-based industries, AgPlenus work on novel herbicides and fungicides, Biomica microbiome-based therapeutics, and Nasdaq listing-compliance matters for EVGN ordinary shares.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Biomica Ltd., a subsidiary of Evogene Ltd. (Nasdaq: EVGN), has successfully closed a financing round totaling $20 million, aimed at advancing its microbiome-based therapeutics. The funding was primarily led by a $10 million investment from Shanghai Healthcare Capital, which now owns 20% of Biomica's shares. The funds will be allocated to complete the BMC128 phase 1 immuno-oncology study and initiate a phase 2 trial, as well as to scale up GMP production of BMC333 for an upcoming phase 1 clinical trial focused on inflammatory bowel disease (IBD). Biomica is dedicated to developing innovative therapeutics utilizing its MicroBoost AI technology, emphasizing treatments for antibiotic-resistant bacteria and gastrointestinal disorders.